Literature DB >> 1594211

Clinical experience with the single-plate Molteno implant in complicated glaucomas. Update of a pilot study.

M A Lloyd1, T Sedlak, D K Heuer, D S Minckler, G Baerveldt, M B Lee, J F Martone.   

Abstract

Ninety-six patients who had undergone single-plate Molteno implantation for glaucomas with poor surgical prognoses were re-evaluated for long-term results. Control of intraocular pressure was achieved with one single-plate implant to a level less than 22 mmHg (but greater than 5 mmHg) without reoperation or devastating complications in 46% of the aphakic/pseudophakic eyes, 25% of eyes after failed filters, 25% of eyes with neovascular glaucomas, and 26% of eyes in patients younger than 13 years of age (life-table analysis at 5 years). Five-year success rates improved to 53%, 71%, 40%, and 56%, respectively, when data from second plates were included. Visual acuities improved or remained the same after one or two plates were implanted in 47% of aphakic/pseudophakic eyes, 17% of eyes after failed filters, 65% of eyes with neovascular glaucomas, and 63% of eyes in patients younger than 13 years of age on whom Snellen acuity was available. The most frequent overall complications after implantation of one or two plates included: corneal edema (19%), corneal graft decompensation (13%), and cornea-tube touch, retinal detachment, and cataract (8% each).

Entities:  

Mesh:

Year:  1992        PMID: 1594211     DOI: 10.1016/s0161-6420(92)31910-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  22 in total

1.  Survival analysis for success of Molteno tube implants.

Authors:  D C Broadway; M Iester; M Schulzer; G R Douglas
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

2.  Combined pars plana vitrectomy and Baerveldt glaucoma implant placement for refractory glaucoma.

Authors:  Thalmon R Campagnoli; Sung Soo Kim; William E Smiddy; Steve J Gedde; Donald L Budenz; Richard K Parrish; Paul F Palmberg; William Feuer; Wei Shi
Journal:  Int J Ophthalmol       Date:  2015-10-18       Impact factor: 1.779

Review 3.  Aqueous shunts for glaucoma.

Authors:  D S Minckler; S S Vedula; T J Li; M C Mathew; R S Ayyala; B A Francis
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 4.  Glaucoma drainage devices; past, present, and future.

Authors:  K S Lim; B D Allan; A W Lloyd; A Muir; P T Khaw
Journal:  Br J Ophthalmol       Date:  1998-09       Impact factor: 4.638

5.  Efficacy and safety of the Ahmed glaucoma valve implant in Chinese eyes with complicated glaucoma.

Authors:  J S Lai; A S Poon; J K Chua; C C Tham; A T Leung; D S Lam
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

6.  Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up.

Authors:  Steven J Gedde; Joyce C Schiffman; William J Feuer; Leon W Herndon; James D Brandt; Donald L Budenz
Journal:  Am J Ophthalmol       Date:  2012-01-15       Impact factor: 5.258

7.  Analysis of long-term outcomes for combined pars plana vitrectomy (PPV) and glaucoma tube shunt surgery in eyes with advanced glaucoma.

Authors:  A Gandhi; D M Miller; J M Zink; A K Khatana; C D Riemann; M R Petersen; R E Foster; R A Sisk
Journal:  Eye (Lond)       Date:  2013-12-13       Impact factor: 3.775

8.  Long term effect on IOP of a stainless steel glaucoma drainage implant (Ex-PRESS) in combined surgery with phacoemulsification.

Authors:  C E Traverso; F De Feo; A Messas-Kaplan; P Denis; S Levartovsky; E Sellem; F Badalà; Z Zagorski; A Bron; S Gandolfi; M Belkin
Journal:  Br J Ophthalmol       Date:  2005-04       Impact factor: 4.638

9.  Partial Tenon's capsule resection with adjunctive mitomycin C in Ahmed glaucoma valve implant surgery.

Authors:  R Susanna
Journal:  Br J Ophthalmol       Date:  2003-08       Impact factor: 4.638

10.  Outcome of graft free Molteno tube insertion.

Authors:  J K Leong; P McCluskey; S Lightman; H M A Towler
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.